Heart Valve Disease – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Heart Valve Disease – Drugs In Development, 2024 report and make more profitable business decisions.
Heart valve diseases are problems affecting one or more of the four valves in the heart, where the heart valve or valves do not open or close properly with every heartbeat, causing disruption of blood flow. Stenosis, regurgitation, and atresia are a few types of heart valve diseases. Signs and symptoms can range from mild to severe, including chest pain, irregular heartbeat (heart murmur), dizziness, shortness of breath, and tiredness. The causes of heart valve diseases are most often idiopathic and congenital, but aging and injury can also be a cause. The condition is diagnosed by ECG, 2D echo, chest x-ray, and CT scan. Heart valve diseases are treatable and treatment options include surgery for serious conditions, valvuloplasty, and management with medications.
The Heart Valve Disease drugs in development market research report provide comprehensive information on the therapeutics under development for Heart Valve Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Heart Valve Disease and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Heart Valve Disease | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 13 molecules, with 12 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Heart Valve Disease therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Heart Valve Disease pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Heart Valve Disease treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Abcentra LLCDaiichi Sankyo Co Ltd
Novartis AG
Rancho Santa Fe Bio Inc
REDNVIA Co Ltd
Spark Biopharma Inc
Tyred Co Ltd
University of Ulsan
Vifor Pharma Management Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Heart Valve Disease reports